<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03303040</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201602186-N</org_study_id>
    <secondary_id>1R01AR072328-01</secondary_id>
    <nct_id>NCT03303040</nct_id>
  </id_info>
  <brief_title>Effect of Diaphragm Stimulation During Surgery</brief_title>
  <official_title>The Effect of Intermittent Hemidiaphragm Stimulation During Surgery on Mitochondrial Function, Single Fiber Contractile Force and Catabolic Pathways in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      During major surgical procedures general anesthesia is used to make the patient unconscious.
      General anesthesia insures that the patient is unaware of any pain caused by surgery. General
      anesthesia also prevents the patient from moving to prevent any potential surgical error. At
      the same time general anesthesia makes it impossible for the patient to breathe. To help the
      patient breathe a breathing tube is placed into the patient's airway and connected to the
      mechanical ventilator. A mechanical ventilator is an artificial breathing pump, which
      delivers gas into a patient's airways.

      The purpose of this research study is to determine if brief periods of diaphragm stimulation
      can prevent diaphragm problems caused by the use of mechanical ventilators and surgery. To
      answer this question the changes in the genes responsible for maintaining diaphragm function
      will be studied. A gene is the code present in each cell in your body and controls the
      behavior of that cell. In addition, the changes in the contractile properties of muscle
      fibers will be studied. The results from this study may help develop new treatments to
      prevent diaphragm weakness resulting from mechanical ventilation use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although mechanical ventilation (MV) is life-sustaining, it comes with a cost. MV
      dramatically reduces diaphragm contractility, induces ventilator-induced diaphragm
      dysfunction (VIDD) and sometimes leads to weaning failure. VIDD includes reduced
      mitochondrial respiration and increased oxidative stress, muscle fiber damage and decreased
      diaphragm force production.

      In animal models, intermittent diaphragm contraction during MV support attenuates VIDD.
      However, there are only limited data addressing this problem in humans. Here, the study team
      propose to directly test the hypothesis that intermittent electrical stimulation (ES) of the
      human hemidiaphragm during prolonged cardiac surgeries with MV support prevents/attenuates
      VIDD in the active hemidiaphragm. Mitochondrial function is central to energy metabolism and
      skeletal muscle function in a chronically active muscle, such as the diaphragm. Although
      abnormal mitochondrial function is thought to precipitate VIDD in animal models, limited data
      are available concerning mitochondrial contributions to VIDD in humans. Of even greater
      importance, there are no interventions available to attenuate these defects in humans. Here,
      the study team will test the impact of an innovative experimental treatment, intermittent
      electrical stimulation (ES) of the hemidiaphragm during prolonged surgeries with MV, on
      mitochondrial function, single fiber contractile properties and catabolic muscle pathways in
      human diaphragm. Using a within-subjects experimental design, muscle samples from a
      stimulated hemidiaphragms will be compared with samples from the unstimulated hemidiaphragm.
      The study team will investigate mitochondrial dysfunction and oxidative stress during
      prolonged CTS/MV, and the potential of ES to attenuate or prevent VIDD. Next, the study team
      will investigate the effects of ES on single fiber contractile properties and Titin
      integrity. Finally, the study team will study the effect of ES on proteolytic pathways
      (caspase, calpain and ubiquitin-proteasome) and ribosomal RNA markers of decreased protein
      synthesis implicated in VIDD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2018</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a within subjects design. One side of each subject's diaphragm will be stimulated. The other side of the subject's diaphragm will not be stimulated and will therefore serve as the control. Biopsies will be taken from both sides and compared.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mitochondrial respiration</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>High-resolution respirometry will be used to assess mitochondrial respiration. It will be quantified as pmol oxygen/sec/mg wet weight.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mitochondrial reactive oxygen species production</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>Mitochondrial reactive oxygen species (ROS) production will be assessed using an in situ approach to measure hydrogen peroxide production in permeabilized diaphragm skeletal muscle fiber bundles. It will be quantified as pmol/min/mg dry weight.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mitochondrial DNA mutation frequency</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>Long-Amplicon quantitative PCR will be used to measure the frequency of mitochondrial DNA mutations. It will be quantified as number of lesions/10 kilobases.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nuclear DNA mutation frequency</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>Long-Amplicon quantitative PCR will be used to measure the frequency of nuclear DNA mutations. It will be quantified as number of lesions/10 kilobases.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aconitase activity</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>In order to evaluate mitochondrial damage, actonitase activity will be measured spectrophotometrically. It will be quantified as units/mg protein.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipid peroxidation</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>Lipid peroxidation will be assessed by measuring 4-hydroxy-2-nonenal-modified proteins. It will be quantified as arbitrary optical density units.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Citrate cynthase activity</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>Changes in electron transport chain will be assessed by measuring citrate cynthase activity. It will be quantifed as nmol/mg protein/min.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytochrome c oxidase (COX) activity</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>Changes in electron transport chain will be assessed by measuring cytochrome c oxidase (COX) activity. It will be quantifed as Units/mcg protein.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Single diaphragm fiber, specific force</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>Single diaphragm fiber mechanical force properties will be measured. Specific force is quantified as kN/m^2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Single diaphragm fiber, rate of tension redevelopment</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>Single diaphragm fiber mechanical force properties will be measured. The rate of tension redevelopment is quantified as s^(-1).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Single diaphragm fiber, maximum shortening velocity</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>Single diaphragm fiber mechanical force properties will be measured. The maximum shortening velocity is quantified as mm/s..</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Titin size</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>Titin integrity will be assessed. A relative titin size will be quantified in nm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total titin to myosin heavy chain ratio</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>Titin integrity will be assessed. The total titin to myosin heavy chain ratio will be presented as a unitless value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Titin exon composition</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>The composition of titin exons will be assessed and quantified via real-time polymerase chain reaction (qPCR). It will be presented as percent change in expression.
as a percent change in expression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Titin binding proteins</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>Titin binding proteins will be assessed and quantified via real-time polymerase chain reaction (qPCR). It will be presented as percent change in expression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Calpain 1</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>Calpain 1 will be measured with Western Blot anaylsis and will be presented as percent difference in expression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Calpain 2</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>Calpain 2 will be measured with Western Blot anaylsis and will be presented as percent difference in expression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Calpain 3</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>Calpain 3 will be measured with Western Blot anaylsis and will be presented as percent difference in expression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Caspase-3</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>Caspase-3 will be measured with Western Blot anaylsis and will be presented as percent difference in expression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Caspase-9</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>Caspase-9 will be measured with Western Blot anaylsis and will be presented as percent difference in expression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>20S proteasome</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>20S proteasome will be measured with Western Blot anaylsis and will be presented as percent difference in expression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>26S proteasome</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>26S proteasome will be measured with Western Blot anaylsis and will be presented as percent difference in expression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MurF1</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>MurF1 will be measured with Western Blot anaylsis and will be presented as percent difference in expression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Atrogin 1</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>Atrogin 1 will be measured with Western Blot anaylsis and will be presented as percent difference in expression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Foxo-3</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>Foxo-3 will be measured with Western Blot anaylsis and will be presented as percent difference in expression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>28SrRNA</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>28SrRNA will be measured with Western Blot anaylsis and will be presented as percent difference in expression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>18SrRNA</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>18SrRNA will be measured with Western Blot anaylsis and will be presented as percent difference in expression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>45S pre-rRNA</measure>
    <time_frame>Up to eight hours</time_frame>
    <description>45S pre-rRNA will be measured with Western Blot anaylsis and will be presented as percent difference in expression.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Mechanical Ventilation Complication</condition>
  <condition>Diaphragm Injury</condition>
  <arm_group>
    <arm_group_label>Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Electrical stimulation of hemidiaphragm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No stimulation of hemidiaphragm</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electrical stimulation of hemidiaphragm</intervention_name>
    <description>Electrical impulses</description>
    <arm_group_label>Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing complex, elective prolonged surgeries usually lasting 5-8 hrs
             (valveoplasty, coronary artery bypass and/or aortic repairs)

        Exclusion Criteria:

          -  History of prior surgery to the diaphragm, phrenic nerves or pleura

          -  Diagnosis of neuromuscular diseases such as amyotrophic lateral sclerosis, multiple
             sclerosis, myasthenia gravis or muscular dystrophy or myopathies

          -  Diagnosis or history of chronic fatigue syndrome, fibromyalgia, dermatomyositis,
             rhabdomyolysis, polymyositis or similar inflammatory muscle diseases

          -  Diagnosis of chronic respiratory diseases such as sarcoidosis, pulmonary hypertension,
             tuberculosis or pulmonary fibrosis

          -  Diagnosis of severe obstructive lung disease as evidenced by an FEV1.0 of &lt;40% of the
             predicted value

          -  Any type of lung cancer or other malignancy

          -  Skeletal pathology such as scoliosis or spinal hardware that may interfere with chest
             wall movements

          -  Uncontrolled hypothyroidism

          -  Use of muscle relaxants, immunosuppressants, or corticosteroid medications within the
             past 28 days

          -  Use of aminoglycoside antibiotics in the previous 28 days

          -  NYHA Class IV heart failure

          -  Requirement for profound hypothermia during surgery (&lt; 25Â°C esophageal temperature)

          -  Any other factor that in the surgeon's opinion would contraindicate participation for
             patient safety purposes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>12 females and 12 males (based on gender identity) will be recruited for the study</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anatole D Martin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas M Beaver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Cobb, PhD</last_name>
    <phone>352-273-7837</phone>
    <email>jessica.cobb@surgery.ufl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anatole D Martin, PhD</last_name>
    <phone>352-273-6105</phone>
    <email>dmartin@phhp.ufl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Beaver, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2017</study_first_submitted>
  <study_first_submitted_qc>October 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2017</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mechanical ventilation</keyword>
  <keyword>Diaphragm weakness</keyword>
  <keyword>Difficulty weaning from mechanical ventilation</keyword>
  <keyword>Diaphragm stimulation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

